JAMP Pharma Corporation

Canada’s first Stelara (ustekinumab) biosimilar has been introduced to the market by Alvotech and marketing partner Jamp Pharma through the latter’s BioJamp unit. The launch comes after the firms

Alvotech and Jamp Pharma have announced approval from Health Canada for their partnered Stelara (ustekinumab) biosimilar, with Alvotech’s AVT04 candidate granted a Canadian marketing authorization

Sandoz Canada and local player JAMP Pharma Corporation have both received approvals from Health Canada for generic versions of Merck & Co’s Januvia (sitagliptin) therapy to improve glycemic control

Alvotech’s multi-biosimilar commercialization deal with Fuji Pharma Co. Ltd. in Japan has begun to bear fruit, with the Japanese firm applying to the Japanese Ministry of Health, Labor, and Welfare